- Home
- STM vs RVMD Comparison
STM vs RVMD Comparison
Compare STM & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STM | RVMD |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7B | 40.3B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STM | RVMD |
|---|---|---|
| Price | $40.61 | $183.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 25 |
| Target Price | $70.46 | ★ $258.84 |
| AVG Volume (30 Days) | ★ 9.6M | 1.9M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.86 | N/A |
| Revenue Next Year | $20.10 | $526.64 |
| P/E Ratio | $187.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.11 | $58.91 |
| 52 Week High | $81.42 | $224.31 |
Technical Indicators
Market Signals| Indicator | STM | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 56.58 |
| Support Level | $43.21 | $198.91 |
| Resistance Level | $52.13 | $207.50 |
| Average True Range (ATR) | 1.88 | 8.24 |
| MACD | 0.16 | 1.42 |
| Stochastic Oscillator | 38.42 | 86.26 |
Price Performance
Historical ComparisonAbout STM STMicroelectronics N.V.
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconducteurs in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.